Last reviewed · How we verify

Drug: Budesonide/formoterol (Symbicort Turbuhaler

AstraZeneca · FDA-approved active Small molecule

Drug: Budesonide/formoterol (Symbicort Turbuhaler is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Small molecule drug developed by AstraZeneca. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Budesonide/formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle.

Budesonide/formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameDrug: Budesonide/formoterol (Symbicort Turbuhaler
SponsorAstraZeneca
Drug classInhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)
TargetGlucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhaseFDA-approved

Mechanism of action

Budesonide is an inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 adrenergic agonist (LABA) that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Drug: Budesonide/formoterol (Symbicort Turbuhaler

What is Drug: Budesonide/formoterol (Symbicort Turbuhaler?

Drug: Budesonide/formoterol (Symbicort Turbuhaler is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) drug developed by AstraZeneca, indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does Drug: Budesonide/formoterol (Symbicort Turbuhaler work?

Budesonide/formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle.

What is Drug: Budesonide/formoterol (Symbicort Turbuhaler used for?

Drug: Budesonide/formoterol (Symbicort Turbuhaler is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes Drug: Budesonide/formoterol (Symbicort Turbuhaler?

Drug: Budesonide/formoterol (Symbicort Turbuhaler is developed and marketed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is Drug: Budesonide/formoterol (Symbicort Turbuhaler in?

Drug: Budesonide/formoterol (Symbicort Turbuhaler belongs to the Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) class. See all Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) drugs at /class/inhaled-corticosteroid-long-acting-beta-2-agonist-combination-ics-laba.

What development phase is Drug: Budesonide/formoterol (Symbicort Turbuhaler in?

Drug: Budesonide/formoterol (Symbicort Turbuhaler is FDA-approved (marketed).

What are the side effects of Drug: Budesonide/formoterol (Symbicort Turbuhaler?

Common side effects of Drug: Budesonide/formoterol (Symbicort Turbuhaler include Tremor, Headache, Palpitations, Oral candidiasis, Nervousness/anxiety, Muscle cramps.

What does Drug: Budesonide/formoterol (Symbicort Turbuhaler target?

Drug: Budesonide/formoterol (Symbicort Turbuhaler targets Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol) and is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA).

Related